Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Chinese Patent Office
Accenture
Cantor Fitzgerald
Julphar
US Department of Justice
Mallinckrodt

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NULYTELY-FLAVORED

« Back to Dashboard

Clinical Trials for Nulytely-flavored

Trial ID Title Status Sponsor Phase Summary
NCT00164151 A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy. Completed Braintree Laboratories Phase 3 The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination.
NCT00164164 HalfLytely Bowel Prep System for Colonoscopy Completed Braintree Laboratories Phase 3 The purpose of the this study was to compare the safety and efficacy of HalfLytely (2L NULYTELY + 20mg bisacodyl) to NULYTELY for preparation prior to colonoscopy.
NCT00689026 Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Takeda Pharmaceuticals North America, Inc. N/A A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
NCT00689026 Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Augusta University N/A A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
NCT00953043 Lubiprostone, Colonic Motility and Sensation Completed National Center for Research Resources (NCRR) Phase 4 This study is being done to evaluate the effects of lubiprostone, a drug approved and used for constipation, on pattern of contractions of the colon and the colon's sensitivity to distension.
NCT00953043 Lubiprostone, Colonic Motility and Sensation Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 This study is being done to evaluate the effects of lubiprostone, a drug approved and used for constipation, on pattern of contractions of the colon and the colon's sensitivity to distension.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nulytely-flavored

Condition Name

Condition Name for Nulytely-flavored
Intervention Trials
Colonoscopy 3
Bowel Preparation for Colonoscopy 1
Bowel Preparation 1
Preparation for Colonoscopy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nulytely-flavored
Intervention Trials
Diabetes Mellitus, Type 2 1
Diabetes Mellitus, Type 1 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nulytely-flavored

Trials by Country

Trials by Country for Nulytely-flavored
Location Trials
United States 9
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nulytely-flavored
Location Trials
Illinois 2
Texas 2
New Hampshire 1
Indiana 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nulytely-flavored

Clinical Trial Phase

Clinical Trial Phase for Nulytely-flavored
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nulytely-flavored
Clinical Trial Phase Trials
Completed 5
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nulytely-flavored

Sponsor Name

Sponsor Name for Nulytely-flavored
Sponsor Trials
Gastroenterology Services, Ltd. 2
Braintree Laboratories 2
National Center for Research Resources (NCRR) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nulytely-flavored
Sponsor Trials
Other 5
Industry 5
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Teva
US Department of Justice
Healthtrust
Harvard Business School
Colorcon
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.